The United States of America as Represented by the Secretary of

The United States of America as Represented by the Department of Health

Giulio L Cantoni

Peter K Chiang

John A Montgomery

Henry H Richards

(.+-.)3-Deazaaristeromycin, also known as (.+-.)-4-amino-1-[(1.alpha., 2.beta., 3.beta., 4.alpha.)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]imidazo[4,5-c]pyridin e, utilized as a novel antiviral agent and inhibiting S-adenosylhomocysteine hydrolase in a pharmacological target in effective concentrations.

(.+-.)3-Deazaaristeromycin and uses

3-Deazaadenosine has been found to be an effective antiviral and antifocal agent in tissue culture of animals as evidenced by its activity against Rous sarcoma virus, influenza virus, vesicular stomatitis virus, Sindbis virus, and Newcastle disease virus in the range 0.03-0.3 mM. This compound has also shown use as an inhibitor of adenosylhomocysteine hydrolase from beef liver in the range of 0.001-0.008 mM (I.sub.50). The antiviral and antifocal effect is correlated with the inhibition of hydrolysis of adenosylhomocysteine in cells. This inhibition of adenosylhomocysteine hydrolase can also be demonstrated in livers of rats injected with 3-deazaadenosine.

Growing community of inventors

Bethesda, MD, United States of America

Giulio L Cantoni